A Neurocomputational Model for Prostate Carcinoma Detection

Cancer

Volumn 98, Issue 9, 2003, Pages 1849-1854

  Kalra, Pankaj ^a   Togami, Joanna ^a   Bansal, Gaurav ^a   Partin, Alan W ^b   Brawer, Michael K ^c   Babaian, Richard J ^d   Ross, Lawrence S ^a   Niederberger, Craig S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c NORTHWEST HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Detection; Neural network; Neurocomputer; Prostate carcinoma screening; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; EARLY DIAGNOSIS; FAMILY HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RACE; RELIABILITY; RISK FACTOR;

AGE FACTORS; AGED; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0142212246     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11748     Document Type: Article

References (39)

1. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Database report on longitudinal observations on prostate cancer. Cancer. 1996;77:2162-2166.
2. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomical radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395-406.
3. Wilkinson S, Chodak G. Informed consent for prostate-specific antigen screening [editorial]. Urology. 2003;61:2-4.
4. Carter HB, Pearson JD. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. Urology. 1999;54:780-786.
5. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
6. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL. Prostate-specific antigen as a screening test for prostate cancer. The United States experience. Urol Clin North Am. 1997;24: 299-306.
7. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452-1455.
8. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J Urol. 1995; 154:407-413.
9. Deliveliotis C, Alivizatos G, Stavropoulos NJ, et al. Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen. Urol Int. 1994;53:186-190.
10. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol. 1999;162:293-306.
11. Cheli CD, Levine RL, Cambetas DR, Kolker JD, Roberts SB. Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign. Urology. 2002;60(4 Suppl 1):53-59.
12. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology. 2001;57:1105-1111.
13. Lilja H, Christensson A, Dahlén U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37:1618-1625.
14. Catalona WJ, Partin AW, Slawin KM, et al. A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease [abstract]. J Urol. 1997; 157:111.
15. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin. 1995;45:8-30.
16. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostatic-specific antigen in black men. N Engl J Med. 1996; 335:304-310.
17. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277-1281.
18. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk for prostate cancer. Prostate. 1990;17:337-347.
19. Lepor H, Owens RS, Rogenes V, Kuhn E. Detection of prostate cancer in males with prostatism. Prostate. 1994;25:132-140.
20. Golden RM. Mathematical methods for neural network analysis and design. Cambridge, MA: MIT Press, 1996.
21. Wilks SS. The large sample distribution of the likelihood ratio for testing composite hypotheses. Ann Math Stat. 1938; 9:60.
22. Okihari K, Cheli CD, Partin AW, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 2002;167:2017-2023; discussion 2023-2024.
23. Duda RO, Hart PE. Pattern classification and scene analysis. New York: John Wiley & Sons, 1973.
24. Wickens TD. Elementary signal detection theory. New York: Oxford University Press, 2002.
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
26. Pienta KJ. Etiology, epidemiology, and prevention of carcinoma of the prostate. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's urology. Philadelphia: W.B Saunders Company, 1998:2489-2496.
27. Powell IJ. Prostate cancer and African-American men. Oncology. 1997;11:599-605; discussion 606-615.
28. Wu AH, Whittemore AS, Kolonel LN, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4:735-741.
29. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol. 1991;146:1305-1307.
30. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA. 1992;89:3367-3371.
31. Latil A, Lidereau R. Genetic aspects of prostate cancer. Virchows Arch. 1998;432:389-406.
32. Gerber GS, Thisted R, Chodak GW, Thompson IM. Disease-specific survival following routine prostate cancer screening by digital rectal examination: corrected patient classification. JAMA. 1993;269:61-64.
33. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology. 1995;45:70-74.
34. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
35. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol. 1999;161:835-839.
36. Christensson A, Björk T, Nilsson O, et al. Serum prostate-specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-105.
37. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995; 274:1214-1220.
38. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542-1547.
39. Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 1998;52:372-378.